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Abstract 
Lung uptake of technetium-labeled hexamethylpropyleneamine oxime (HMPAO) increases in rat models of 
human acute lung injury, consistent with increases in lung tissue glutathione (GSH). Since 99mTc-HMPAO uptake 
is the net result of multiple cellular and vascular processes, the objective was to develop an approach to 
investigate the pharmacokinetics of 99mTc-HMPAO uptake in isolated perfused rat lungs. Lungs of anesthetized 
rats were excised and connected to a ventilation-perfusion system. 99mTc-HMPAO (56 MBq) was injected into the 
pulmonary arterial cannula, a time sequence of images was acquired, and lung time-activity curves were 
constructed. Imaging was repeated with a range of pump flows and perfusate albumin concentrations and 
before and after depletion of GSH with diethyl maleate (DEM). A pharmacokinetic model of 99mTc-HMPAO 
pulmonary disposition was developed and used for quantitative interpretation of the time-activity curves. 
Experimental results reveal that 99mTc-HMPAO lung uptake, defined as the steady-state value of the 99mTc-
HMPAO lung time-activity curve, was inversely related to pump flow. Also, 99mTc-HMPAO lung uptake decreased 
by ~65% after addition of DEM to the perfusate. Increased perfusate albumin concentration also resulted in 
decreased 99mTc-HMPAO lung uptake. Model simulations under in vivo flow conditions indicate that lung tissue 
GSH is the dominant factor in 99mTc-HMPAO retention in lung tissue. The approach allows for evaluation of the 
dominant factors that determine imaging biomarker uptake, separation of the contributions of pulmonary 
versus systemic processes, and application of this knowledge to in vivo studies. 
NEW & NOTEWORTHY We developed an approach for studying the pharmacokinetics of technetium-labeled 
hexamethylpropyleneamine oxime (99mTc-HMPAO) in isolated perfused lungs. A distributed-in-space-and-time 
computational model was fit to data and used to investigate questions that cannot readily be addressed in vivo. 
Experimental and modeling results indicate that tissue GSH is the dominant factor in 99mTc-HMPAO retention in 
lung tissue. This modeling approach can be readily extended to investigate the lung pharmacokinetics of other 
biomarkers and models of lung injury and treatment thereof. 
INTRODUCTION 
Technetium-labeled hexamethylpropyleneamine oxime (99mTc-HMPAO) is a radiolabeled compound used in 
clinical single-photon emission tomography (SPECT) brain perfusion imaging because of its prolonged flow-
dependent retention (17). In addition, increased 99mTc-HMPAO lung uptake has been reported in patients with 
lung injury resulting from chemotherapy and radiation injury in the absence of perfusion impairment or 
roentgenographic abnormalities (25) and in patients with diffuse infiltrative lung disease (13). Also, we and 
others have reported the potential utility of 99mTc-HMPAO imaging for detecting and monitoring lung injury in 
preclinical models involving prolonged exposure to high concentrations of oxygen (hyperoxia) (4, 5, 10), the 
sepsis mimic lipopolysaccharide (6), and chemotoxic agents (12). These studies revealed increased lung uptake 
in subjects with subclinical lung injury, suggesting that 99mTc-HMPAO imaging may be a means for quantitatively 
detecting lung injury before detection with conventional clinical tools and for assessing the efficacy of novel 
therapies (5). 
HMPAO exists in two forms: the oxidized cell-permeant form and the reduced cell-impermeant form (20). The 
oxidized form is highly lipophilic, with an octanol-water partition coefficient of ~83, compared with 0.006 for the 
reduced form (2). Thus 99mTc-HMPAO uptake is dependent on the rate of diffusion of the oxidized form across 
the cell membrane, where once across the cell membrane it is converted to its reduced cell-impermeant form 
and retained within the tissue or diffuses back to the blood. The intracellular conversion and retention of 
HMPAO are dependent in part on the oxidoreductive state of the tissue including the intracellular content of the 
antioxidant glutathione (GSH) (4, 20). 
Lung tissue GSH content increases in response to oxidative stress, which plays a key role in the pathogenesis of 
lung diseases, including acute lung injury (16, 21). We and others have demonstrated that the lung uptake of 
HMPAO is dependent on lung tissue GSH content (4–6) and hence can serve as a biomarker of lung tissue GSH 
content. However, lung uptake of 99mTc-HMPAO is the net result of multiple cellular and vascular processes, 
including cardiac output, plasma and tissue GSH content, plasma protein binding, uptake by other organs, 
capillary endothelial permeability, and mitochondrial and/or cytosolic redox status (1, 17, 19, 20). Each of these 
cellular and vascular processes, most of which cannot be assessed in vivo, can vary with acute illness. Thus 
clinical use of 99mTc-HMPAO for assessing lung pathology necessitates knowledge of the sensitivity and 
specificity of uptake to changes in the targeted lung cellular process (i.e., GSH content) induced by the disease 
pathology versus alteration of some other process(es) (e.g., cardiac output, vascular permeability, input 
function) (4, 17). 
The objective of this study was to use 99mTc-HMPAO imaging of an isolated perfused lung (IPL) to readily and 
knowingly manipulate the vascular and tissue processes hypothesized to determine 99mTc-HMPAO lung uptake. 
The pharmacokinetics of 99mTc-HMPAO uptake in the lung were investigated via experimental studies, and a 
physiologically based pharmacokinetic (PBPK) model (8, 9) descriptive of 99mTc-HMPAO disposition in the lung 
was used to estimate parameters descriptive of the various processes. 
There is ample evidence that the lung uptake of 99mTc-HMPAO is relatively fast on passage through the 
pulmonary circulation (4, 6, 10). Thus the assumption of well-mixed compartments made by existing models 
for 99mTc-HMPAO brain pharmacokinetics (1, 2, 17, 20) may not be appropriate in the lung, especially since lung 
capillary perfusion is highly heterogeneous, with some pathways having short transit times and other having 
long transit times (23). Furthermore, the injected bolus contains the oxidized form of 99mTc-HMPAO, which is 
highly lipophilic (2). Thus we developed a distributed-in-space-and-time PBPK model for interpretation of the 
measured lung time-activity curves (TACs). 
MATERIALS AND METHODS 
HMPAO (Ceretec) was purchased in kit form from GE Healthcare (Arlington Heights, IL). Diethyl maleate (DEM) 
and other reagent-grade chemicals were purchased from Sigma-Aldrich (St. Louis, MO). 
Experimental methods. 
This protocol was approved by the Institutional Animal Care and Use Committee of the Department of Veterans 
Affairs Medical Center (Milwaukee, WI). Adult male Sprague-Dawley rats [352 ± 7 (SE) g, n = 11] were 
anesthetized (pentobarbital sodium, 40–50 mg/kg), the lungs were excised, and the pulmonary artery, 
pulmonary vein, and trachea were cannulated and connected to a ventilation-perfusion system as previously 
described (23). The lungs were oriented in the upright position. Krebs-Ringer bicarbonate perfusate with 3% or 
5% bovine serum albumin (BSA) was maintained at 37°C (pH = 7.4) (21), and lungs were ventilated at 40 
breaths/min (15% O2, 6% CO2, balance N2) with end-inspiratory and end-expiratory airway pressures of ~6 and 
3 mmHg, respectively. 
A modular gamma camera (4.5 in. × 4.5 in.) attached to a parallel-hole collimator of a micro-SPECT system was 
oriented vertically (4, 10). The collimator was positioned ~4 cm from the lung to maximize detection efficiency. 
HMPAO was conjugated with pertechnetate (TcO4
−) according to kit directions. Each experiment began with 
imaging of a calibration phantom (1.7-mL Eppendorf cuvette) containing ~150 MBq of pertechnetate, positioned 
next to the lung. A bolus of 99mTc-HMPAO (~56 MBq in 0.2 mL) was loaded into an injection loop with two 
parallel tubing segments, positioned upstream from the arterial cannula. At end-expiration, the ventilator was 
stopped and the solenoid valve in the injection loop was activated to divert the lung inflow to the 99mTc-HMPAO 
segment, without changing pressure or flow. Dynamic planar images were acquired every second for 1–2 min 
(depending on flow) as the 99mTc-HMPAO bolus perfused the lung in this single-pass system. Ventilation was 
restored upon completion of the imaging sequence. To evaluate the effect of perfusate flow on 99mTc-HMPAO 
uptake, repeated bolus injections and imaging were performed with flows of 5, 10, and 15 mL/min and 3% BSA 
perfusate. To determine the effect of protein in the perfusate, bolus injections and imaging were performed 
with perfusate containing either 3% or 5% BSA at a flow of 10 mL/min. To determine the impact of the GSH 
concentration in the lung, DEM (6 mM) was added to the perfusate reservoir and circulated through the lung for 
10 min before 99mTc-HMPAO bolus injection and imaging. 
Image analysis. 
For each bolus injection, the time sequence of planar images was analyzed to determine the lung TAC 
describing 99mTc-HMPAO lung uptake as a function of time (10). The sum of the time sequence of images was 
displayed, and a region of interest (ROI) corresponding to the lung was manually outlined with ImageJ. Since 
knowledge of the input curve to the lung is required for PBPK modeling (24), an ROI was also drawn over the 
inflow cannula. The resulting ROI masks were then superimposed on the sequence of 99mTc-HMPAO images and 
used to calculate TAC curves representing mean counts per pixel within both the lung and input ROIs for each 
time frame. The preinjection baseline was subtracted from the curve to account for residual 99mTc-HMPAO from 
the previous injection, followed by normalization to the injected dose and to the calibration phantom to obtain 
the TAC in units of mean counts per pixel per second per injected dose for each ROI. Lung uptake was 
determined as the mean of the lung TAC over the last 5 s of data acquisition, i.e., at steady state. 
The image of the calibration phantom was used to calculate the fraction of injected 99mTc-HMPAO retained in 
the lung. An ROI was drawn over the image of the phantom, and total counts acquired over 5 s were determined 
from the phantom ROI. The known activity within the phantom was divided by the ROI counts to determine an 
image count-to-activity conversion factor. Total counts acquired from the lung image ROI over the last 5 s of 
imaging were also determined and converted to lung activity with this conversion factor. The fraction of 99mTc-
HMPAO retained in the lung was then calculated as lung activity divided by the known activity injected into the 
lung. 
BSA concentration in perfusate. 
The influence of perfusate BSA concentration on the fraction of oxidized 99mTc-HMPAO bound to BSA was 
studied with a Centrifree Ultrafiltration Device with Ultracel PL membrane (30,000 NMWL) (Millipore Sigma, St. 
Louis, MO) as previously described (11). Perfusate solutions with BSA concentrations of 1.5%, 3%, and 5% (pH 
7.4) were prepared. For a given concentration, 0.4 mL of 99mTc-HMPAO (~220 MBq/mL) was added to 1.6 mL of 
perfusate; 0.1 mL of the mixture was placed in a 1-mL Eppendorf tube (sample 1), and another 0.8 mL was 
transferred to the upper portion of the device. The device was then centrifuged for 3 min (2,000 g, 37°C); 0.1 mL 
of the filtrate was then added to a different Eppendorf tube (sample 2). Activity in samples 1 and 2 was then 
counted to obtain measures of total (BSA-bound + free) and free 99mTc-HMPAO in the perfusate. 
EXPERIMENTAL RESULTS 
Representative image frames acquired during 99mTc-HMPAO passage through the isolated lung, with pump flow 
(F) = 10 mL/min and 3% BSA perfusate, are shown in Fig. 1. The corresponding inlet and outlet TACs are shown 
in Fig. 2. The lung TAC consists of a throughput portion that dominates the early part of the curve and a tissue 
uptake and retention portion that dominates the later, steady-state portion of the curve. The steady-state 
portion is consistent with the reduced form being tissue impermeant. 
 
Fig. 1. Representative image frames acquired during 99mTc-HMPAO passage through an isolated perfused lung 
showing arterial input and lung regions of interest. Color scale represents counts/s. 
 
 
Fig. 2. Representative arterial input and lung time-activity curves (TACs) after bolus injection of 99mTc-HMPAO 
with 3% bovine serum albumin perfusate at pump flow = 10 mL/min. Curves normalized to injected dose 
(ID). Lefty-axis is for input; righty-axis is for lung. 
 
At F = 10 mL/min with 3% BSA perfusate, 35.9 ± 4.7% (SE; n = 8 rats) of the injected dose was retained in the lung 
tissue during a single pass through the pulmonary circulation, consistent with the relatively high lipophilicity of 
the oxidized form of 99mTc-HMPAO. 
To determine the effect of flow on lung uptake of 99mTc-HMPAO, experiments were repeated at F = 5, 10, and 15 
mL/min with 3% BSA perfusate. Representative lung TACs shown in Fig. 3A show that lung uptake, as measured 
by the steady-state value of the lung TAC, was inversely related to F. Increasing F from 5 to 10 mL/min resulted 
in a 36% decrease (paired t test, P < 0.001) in steady-state lung uptake (4.30 ± 0.30 at 5 mL/min vs. 2.74 ± 0.27 at 
10 mL/min, n = 8 rats), as shown in Fig. 4. Increasing F to 15 mL/min did not result in a statistically significant 
decrease in uptake (2.33 ± 0.15, n = 5 rats). 
 
Fig. 3. Representative 99mTc-HMPAO lung time-activity curves. A: pump flow (F) = 5, 10, and 15 mL/min [3% 
bovine serum albumin (BSA)]. B: 3% and 5% BSA perfusate at F = 10 mL/min. C: pre- and post-diethyl maleate 
(DEM) at F = 5 mL/min. D: pre- and post-DEM at F = 10 mL/min. Curves normalized to injected dose (ID). 
 
 
Fig. 4.99mTc-HMPAO lung uptake obtained under different experimental conditions, with 3% bovine serum 
albumin (BSA) unless indicated otherwise. Numbers of rats in groups are indicated in the bars. *P < 0.05 in all 
cases. DEM, diethyl maleate. 
 
The effect of perfusate BSA concentration on lung uptake of 99mTc-HMPAO was evaluated with F = 10 mL/min, 
with resulting TACs shown in Fig. 3B. Increasing BSA concentration from 3% (2.74 ± 0.27, n = 8 rats) to 5% 
(1.92 ± 0.19, n = 7 rats) resulted in a ~30% decrease (P = 0.034, unpaired t test) in lung uptake (Fig. 4). This is 
consistent with a decrease in the fraction of injected lipophilic 99mTc-HMPAO available for uptake on passage 
through the lung with increased BSA concentration. 
Figure 5 shows the relationship between perfusate %BSA and the ratio of bound (Bo)-to-free (Fr) 99mTc-HMPAO 
in perfusate. The binding reaction 





Fig. 5. Ratio of bovine serum albumin (BSA) bound to 99mTc-HMPAO to free BSA in perfusate as a function of BSA 
concentration in perfusate. Means ± SD; n = 4 rats. r2   =  0.84 
 







where 𝐾Dv is the equilibrium dissociation constant in units of %BSA. Data in Fig. 5 support this linear 
relationship, consistent with rapidly binding equilibrium between BSA and 99mTc-HMPAO. The slope of the 
regression line through the data yielded an estimated value of 𝐾Dv = 1.46%BSA, which was used in the model 
fitting and simulations below. This result suggests that when perfusate BSA concentration was 3%, ~68% 
of 99mTc-HMPAO in perfusate was bound to BSA. 
The effect of lung tissue GSH content was evaluated by adding DEM to the perfusate, with representative TACs 
shown in Fig. 3, C and D. DEM decreased lung uptake by 62% (4.46 ± 0.42 pre-DEM vs. 1.66 ± 0.14 post-DEM, n = 
4 rats; paired t test, P = 0.004) at a flow of 5 mL/min and by 67% (2.93 ± 0.49 pre-DEM vs. 0.98 ± 0.17 post-
DEM, n = 4 rats; paired t test, P = 0.009) at 10 mL/min (Fig. 4). These results are consistent with a dominant role 
for lung tissue GSH content in uptake and retention of 99mTc-HMPAO on passage through the pulmonary 
circulation. 
PBPK MODEL OF 99mTc-HMPAO PULMONARY DISPOSITION 
Model development. 
A distributed-in-time-and-space model (8) was developed and used for quantitative interpretation of the 
measured lung TACs. The model incorporates the dominant cellular and vascular processes hypothesized to 
determine the pulmonary disposition of 99mTc-HMPAO. A system of partial differential equations (PDEs) was 
constructed that relaxes the assumption of well-mixed compartments and accounts for perfusion heterogeneity 
within the pulmonary capillary region. The whole organ model then consists of conducting arteries and veins, 
and capillary elements, each composed of a vascular region and its surrounding extravascular (tissue) region as 
depicted in Fig. 6. A detailed derivation of the lung model, including the model PDEs, is presented in 
the Appendix. Briefly, the injected oxidized form of 99mTc-HMPAO (𝑂𝑣) enters the capillary region, where it can 
participate in rapidly equilibrating interactions with BSA in the perfusate with dissociation rate constant 𝐾𝐷𝑣, 
diffuse into the extravascular region (PS), or exit the lung. Within the extravascular region, the oxidized form 
(𝑂𝑒) converts to the reduced form (𝑅𝑒) via either a GSH-dependent (𝑘𝐺𝑆𝐻) pathway or other reductant (RH, GSH 
independent, 𝑘𝑅𝐻) pathway that is retained, participates in rapidly equilibrating interactions with protein 
(dissociation rate constant 𝐾𝐷𝑒), or diffuses back into the vascular region of the capillaries. The oxidized form in 
the vasculature exits the capillary region via the conducting veins. 
 
Fig. 6. Model of dominant processes involved in 99mTc-HMPAO (O, oxidized; R, reduced) distribution in a single 
capillary element consisting of vascular (v, blood) and surrounding extravascular (e, cell/tissue) regions. GSH, 
glutathione; V, volume; z, distance from the capillary inlet; RH, GSH-independent reductant; 𝐶𝑖𝑛, capillary input 
function; 𝐶𝑜𝑢𝑡, capillary outlet function; PS, permeability surface-area product; BSA, protein. 
 
The resulting PDEs describing the spatial and temporal changes in the concentration of oxidized and 
reduced 99mTc-HMPAO in the vascular and extravascular regions of a capillary element derived in 





































) − 𝑘GSH?̅?v − 𝑘RH?̅?v (3) 
𝜕𝑅e
𝜕𝑡
= 𝑘GSH?̅?v + 𝑘RH?̅?v (4) 
where ?̅?v(𝑧, 𝑡)  is total concentration of free and BSA-bound oxidized 
99mTc-HMPAO in the vascular region at 
normalized distance z from the capillary inlet at time t, Ō𝑒(𝑧, 𝑡) is total concentration of free and bound 
oxidized 99mTc-HMPAO in the extravascular region, 𝑅𝑒(𝑧, 𝑡) is the concentration of reduced 
99mTc-HMPAO in the 
extravascular region, and the model parameters are defined in Table 1. 
Table 1. Model parameters 
Unknown 
Parameters 
Definition Estimated Value 
𝑘𝐺𝑆𝐻 GSH-dependent reduction rate constant in extravascular region 0.071 ± 0.030 s
−1 
𝑘𝑅𝐻 GSH-independent reduction rate constant in extravascular 
region 
0.031 ± 0.005 s−1 





Ratio of protein concentration to equilibrium dissociation rate 
constant for oxidized HMPAO bound to protein in extravascular 
region 
1.12 ± 0.66 
Given Parameters Definition Fixed Value 
𝑉𝑣 Capillary vascular volume 0.42 mL 
𝑉𝑒 Extravascular tissue volume 1.0 mL 





Ratio of BSA perfusate concentration to equilibrium dissociation 
rate constant for oxidized HMPAO bound to BSA in vascular 
region 
1.06 
BSA, bovine serum albumin; GSH, glutathione; HMPAO, hexamethylpropyleneamine oxime. 
Equations 2–4 are for a single capillary element. To account for the effect of capillary perfusion kinematics on 
the lung uptake of 99mTc-HMPAO, a heterogeneous distribution of pulmonary capillary transit times, ℎ𝑐(𝑡), was 
used as described previously (23). ℎ𝑐(𝑡) was represented with a gamma variate function (18) with mean transit 
time 𝜇𝑐  = 2.5 s and variance σc
2 = 4.0 𝑠2 at F = 10 mL/min as determined previously (23). The ℎ𝑐(𝑡) at F = 5 (or 15) 
mL/min was obtained by rescaling ℎ𝑐(𝑡) by dividing t by 5/10 (or 15/10) and by multiplying its amplitude by 5/10 
(or 15/10) (23). 
The lung input curve, 𝐶𝑎𝑟𝑡(𝑡), was assumed to take the form of a shifted gamma variate function, which was fit 
to the experimental lung inlet TAC for each data set. The arterial and venous transit time distributions were each 
represented by a shifted impulse function with each shift equaling 50% of the noncapillary portion of the lung 
vascular mean transit time (23). Random coupling conditions were assumed between the arteries and the 
capillaries, i.e., all capillary elements are exposed to the same capillary input (3, 23). 
To reduce computation time, Eqs. 2–4 for a single capillary element were solved for the capillary with the 
longest transit time and then subsampled at axial points to obtain individual outflow concentration curves for 
capillaries with shorter transit times (3, 23). The lung output curve, 𝐶𝑣𝑒𝑖𝑛(𝑡), was then computed as the sum of 
all capillary outflow curves, each weighted according to ℎ𝑐(𝑡), and then shifted by the venous transit time. 
Finally, the model lung time-activity curve describing the total amount of 99mTc-HMPAO in the lung as a function 
of time, TAC(t), was obtained with 




Model fitting results. 
Nonlinear regression was used to fit the model solution TAC(t) to the experimental lung TACs to obtain 
estimates of 𝑘𝐺𝑆𝐻, 𝑘𝑅𝐻, permeability surface area product (PS), and ratio of protein concentration to equilibrium 
dissociation rate constant for oxidized HMPAO bound to protein in extravascular region (𝐷𝑒) (Table 1). To reduce 
correlation between the model parameters, two lung TACs obtained from the same lung, namely pre-DEM and 
post-DEM at F = 10 mL/min, were fit simultaneously. In this procedure, 𝑘𝑅𝐻, PS, and 𝐷𝑒 were free parameters 
but assumed equal for both data sets, whereas 𝑘𝐺𝑆𝐻 was free for pre-DEM data but set to zero for post-DEM 
data. This approach is based on the assumption that tissue GSH is depleted after DEM administration. The 
capillary volume, 𝑉𝑣, was fixed at 0.46 mL (23) whereas the extravascular volume, 𝑉𝑒, was set to 1.0 mL based on 
lung tissue water volume estimated from lung wet weight and wet-to-dry weight ratio (6). 𝐷𝑣   =   𝑃𝑣/𝐾𝐷𝑣 was set 
to 3/1.46 since experiments were performed with 𝑃𝑣 = 3%BSA perfusate and the value obtained above for 𝐾𝐷𝑣. 
µ𝑐 was set at 2.5 s as indicated above. The model fitting was done in MATLAB with the lsqcurvefit function that 
implemented the trust-region-reflective algorithm, an iterative optimization algorithm that readily incorporates 
bounds on the values of the parameters. Each model fit was repeated 10 times using randomly generated initial 
parameter values to avoid trapping in a local minimum solution. The largest difference between final parameter 
estimates for all data fits was <0.5%, which provides reasonable confidence that a global minimum was reached 
in all cases. 
A representative result in Fig. 7A, obtained at F = 10 mL/min, shows good agreement between the data (points) 
and the model fit (lines). Figure 8 (pre-DEM Fig. 8, left; post-DEM, Fig. 8, right) shows the corresponding 
sensitivity functions that represent the normalized change in the model-fit TAC(t) for a 1% change in the value of 
each free parameter (7). Note that the 𝑘𝐺𝑆𝐻 and 𝑘𝑅𝐻 functions have the identical shape and are superimposed 
for the pre-DEM case, whereas the 𝑘𝐺𝑆𝐻 function for post-DEM is zero. Each of the others is different from the 
others, suggesting that pre- and post-DEM lung TACs have sufficient information for estimating the model 
parameters. 
 
Fig. 7. Representative experimental lung time-activity curves (TACs; points) and simultaneous model fits 
(lines). A: data acquired before (pre-) and after (post-) diethyl maleate (DEM) treatment [pump flow (F) = 10 
mL/min]. B: data acquired at 3 different flows and model curves obtained with mean ± 1 SD of previously 
estimated model parameters given in Table 1. ID, injected dose. 
 
Table 2. Baseline model parameters 
Model Function or Parameter Parameter Value 
F 100 mL/min 
𝐶𝑖𝑛(𝑡) µ = 0.24 s; σ
2 = 0.046 𝑠2 
ℎ𝑐(𝑡) µ𝑐 = 0.25 s; σ2cσc2 = 0.040 𝑠
2 
Arterial transit µ𝑎 = 0.1 s; σ2aσa2 = 0 
Venous transit µ𝑣 = 0.1 s; σ2vσv2 = 0 





𝑃𝑆 125 mL/s 
𝐷𝑒 1.1 
BSA, bovine serum albumin; 𝐶𝑖𝑛(𝑡), capillary input function; De, ratio of protein concentration to equilibrium 
dissociation rate constant for oxidized HMPAO bound to protein in extravascular region; ℎ𝑐(𝑡), capillary transit 
time distribution; 𝑘𝐺𝑆𝐻, glutathione (GSH)-dependent reduction rate constant; 𝑘𝑅𝐻, GSH-independent reduction 
rate constant; PS, permeability surface area product; μ, mean transit time; 𝜎2, variance. 
 
 
Fig. 8. Model parameter sensitivity functions showing the change in the model solution given a 1% increase in 
the value of the model parameter. Left: pre-diethyl maleate (DEM). Right: post-DEM. Each plot is normalized to 
its maximum value. Parameters given in Table 1. 
 
Table 1 shows the resulting estimated model parameters obtained from four different lungs. The GSH-
dependent rate of HMPAO reduction (𝑘𝐺𝑆𝐻) is ~130% larger than that for the GSH-independent rate of HMPAO 
reduction (𝑘𝑅𝐻), consistent with lung tissue GSH being the dominant factor in HMPAO retention in lung tissue. 
The estimated value of PS is large compared with the flow range studied, consistent with the oxidized form of 
HMPAO being highly lipophilic with a large octanol-water partition coefficient. 
The model was validated by using it in the forward mode with the estimated parameter values in Table 1 to 
predict lung TACs. Figure 7B shows experimental lung TACs obtained from the same rat lung, but not one used in 
the summary results of Table 1, at different pump flows together with corresponding model fits. In this case, the 
model was fit to the three-flow experimental TACs simultaneously while allowing the free model parameters to 
range within 1 SD of the mean values given in Table 1. Good agreement between the data and the resulting 
model TAC is observed at all three flows. 
The model was also used to predict the resulting lung TACs with a pump flow of 5 mL/min to compare with the 
corresponding data TACs for the four rat lungs used in Table 1. The mean of the last five data points of each TAC 
was compared to the steady-state value of the predicted TAC, yielding a relative error of −3.8 ± 6.0 (SD) % in the 
lung uptake values. 
Similarly, the model was used to predict the resulting lung TACs with 3% and 5% BSA concentration, F = 10 
mL/min, and the mean estimated parameters in Table 1. The resulting model steady-state values were 2.86 and 
2.00 for 3% and 5%, respectively, compared with 2.74 ± 0.27 and 1.92 ± 0.19, respectively for the data values 
in Fig. 4, a difference of <5% in both cases. This result provides additional support for the model assumption of 
rapidly equilibrating interactions between 99mTc-HMPAO and perfusate BSA. 
Simulation results. 
Simulations were performed to address questions pertinent to in vivo conditions that cannot be readily 
answered experimentally. A flow of 100 mL/min, corresponding to resting cardiac output of an adult male 350-g 
Sprague-Dawley rat (15), was used to determine the effect of the key model parameters on steady-state lung 
uptake. The baseline simulation was performed with model parameters in Table 2, which were rescaled from 
experiments performed with F = 10 mL/min or obtained from previous studies (23). 
Acute lung injury is often accompanied by substantial changes in cardiac output and blood pressure in patients, 
especially when accompanied with vital mechanical ventilation (20). Simulations were performed in which the 
flow rate through the lung was set at 50, 100, or 150 mL/min, while the volume of each vascular component was 
held constant. The steady-state values of the simulated lung TACs were determined and normalized to the 
F = 100 mL/min baseline case. Results in Fig. 9 show that steady-state lung uptake is inversely related to F, in 
that a 50% decrease in F resulted in a ~13% increase in lung uptake, whereas a 50% increase in F resulted in a 
~8% decrease. This is expected since decreased F allows longer capillary residence times and hence increased 
uptake. 
 
Fig. 9. Lung uptake normalized to baseline case simulated with pump flow = 100 mL/min and parameters given 
in Table 2. Each parameter was increased or decreased by 50%. 
 
Previous studies have shown that in a hyperoxic model of acute lung injury vascular endothelial permeability is 
increased by more than ~200% (6). Figure 9 shows that in simulations when PS was varied by ±50%, steady-state 
lung uptake changed by <1%. Because the estimated value of PS is so large, these flow changes have no 
measurable effect on the steady-state value of 99mTc-HMPAO uptake, which is consistent with the sensitivity 
functions of Fig. 8. 
Since previous studies have demonstrated that tissue GSH content plays a key role in 99mTc-HMPAO retention 
(4–6, 20), simulations were performed in which 𝑘𝐺𝑆𝐻 was changed. Figure 9 shows that steady-state uptake 
increases with 𝑘𝐺𝑆𝐻, consistent with more intracellular HMPAO reduction and retention. 
Data in Fig. 3, C and D, suggest an alternate pathway for 99mTc-HMPAO conversion since there is substantial 
uptake even when GSH is depleted in the lung after DEM treatment. Although specific pathways have not been 
clearly identified, there is evidence that mitochondrial dysfunction and/or endothelial amine metabolism 
dysfunction may be contributors (4). To investigate the contribution of a GSH-independent process, simulations 
were performed with 𝑘𝑅𝐻  changed by ±50%. The resulting steady-state values (Fig. 9) increased with 
increasing 𝑘𝑅𝐻, although the changes were smaller than those resulting from corresponding changes in 𝑘𝐺𝑆𝐻. 
DISCUSSION 
An experimental and computational approach for mechanistic and quantitative evaluation of the 
pharmacokinetics of 99mTc-HMPAO in the rat IPL was developed. The approach allows for evaluation of the 
dominant factors that determine lung uptake of 99mTc-HMPAO and for separation of the contributions of 
pulmonary processes from systemic processes. 
The model accounts for spatial and temporal variations in the concentration of 99mTc-HMPAO on passage 
through the pulmonary capillaries. The model relaxes the assumption of well-mixed compartments made in 
models of 99mTc-HMPAO pharmacokinetics in other organs. The results of the model simulations demonstrate 
the utility of 99mTc-HMPAO for probing tissue GSH content in intact functioning lungs and in vivo. 
Sepsis, a leading cause of acute lung injury, often causes lower and variable cardiac output and blood pressure in 
patients and frequently requires mechanical ventilation (22). Moreover, serum albumin can drop by half in <24 
h. Data here reveal that such changes could affect lung uptake of 99mTc-HMPAO independent of a change in lung 
tissue GSH content. 
In the experiments presented, increasing flow from 5 to 10 mL/min, but not 10 to 15 mL/min, resulted in a 
significant decrease in steady-state 99mTc-HMPAO lung uptake (Fig. 4). The pulmonary vasculature consists of 
distensible blood vessels whose diameters and hence volumes are dependent on the intravascular pressure. 
Previous studies using this IPL preparation showed that the microvascular pressure [(arterial pressure + venous 
pressure)/2] increases from ~3 torr to ~4 torr when flow is increased from 10 to 15 mL/min (23). This increase in 
intravascular pressure results in a ~6% increase in pulmonary vascular volume (14), which is offset by the 50% 
increase in flow, leading to a smaller overall decrease in lung vascular mean transit time. This increase in volume 
that occurs with increased flow may explain the relatively small decrease in 99mTc-HMPAO lung uptake as flow 
was increased from 10 mL/min to 15 mL/min in the experiments. This effect of flow-induced changes in 
microvascular pressure on lung vascular volume could be mitigated in the IPL experiments by adjusting the 
venous pressure to minimize the change in microvascular pressure as pump flow is changed. 
Experimental results show that before the addition of DEM 32 ± 4% of the injected 99mTc-HMPAO was taken up 
and retained in the isolated lung at a flow of 10 mL/min, whereas after DEM this was decreased to 14 ± 4%. The 
pre-DEM fraction is much larger than the 7.4% lung retention in vivo reported by Neirinckx et al. (20). This 
difference is largely due to the large difference between the pump flow (10 mL/min) and the much higher 
resting cardiac output of an adult Sprague-Dawley rat (~100 mL/min) (15). In this case 99mTc-HMPAO lung uptake 
predicted by the model using the parameters in Table 1 is ~6%, providing additional validation of the model. 
In the IPL studies here, and the corresponding model, there was no GSH in the perfusate. The presence of GSH in 
blood plasma (~20 μM) would partially reduce 99mTc-HMPAO and hence decrease the fraction of the oxidized 
form of 99mTc-HMPAO entering the lungs. At a flow of 100 mL/min, model simulations showed that decreasing 
the fraction of oxidized 99mTc-HMPAO entering the lungs by 10%, 20%, or 30% decreased steady-state lung 
uptake by a corresponding ~10%, 20%, and 30%. 
There is strong evidence that oxidative stress plays an important role in the early stages of acute respiratory 
distress syndrome (22), yet there are no good biomarkers for detection of injury before evidence of clinical 
respiratory distress or infiltrates on computed tomography imaging. Unlike prior markers of lung injury that 
target changes in pulmonary endothelial permeability, which is altered later in the disease progression, GSH 
tissue content and the corresponding increase in lung 99mTc-HMPAO uptake occur early in the disease process 
(6). In addition, our investigation of 99mTc-HMPAO is motivated by its status as a clinically approved SPECT 
radiopharmaceutical in routine use. 
The proposed experimental and modeling approach could be readily modified for evaluating key cellular 
processes in other lung injury models by incorporating appropriate differential equations accounting for those 
processes into the computational model. Also, the approach could be used directly to investigate changes in the 
key model parameters that occur with lung injury and hence assess the efficacy of therapeutic treatments 
thereof. The model could also be modified to quantify uptake of other biomarkers in the lung or other organs 
(e.g., heart) or for analyzing data from other functional imaging modalities (e.g., MRI, PET). Moreover, the 
approach can be extended to a whole body model to assess the impact of systemic circulation on the lung 
uptake of HMPAO. 
Model simulations performed at normal cardiac output for a rat indicated that the dominant process in steady-
state uptake of 99mTc-HMPAO was GSH dependent (Fig. 9). To a lesser extent, flow played a role, but that only 
became apparent when flow was changed by 50%. Changes in PS, which might be expected as a result of 
vascular injury, had no effect on uptake, presumably because of the high lipophilicity of the oxidized form 
of 99mTc-HMPAO. These results have important implications for in vivo preclinical studies and potential clinical 
use of 99mTc-HMPAO where presumably only one time-averaged SPECT image volume would be acquired ~30 
min after injection. Any observed increase in 99mTc-HMPAO in the lungs could, with fair confidence, be attributed 
to an increase in a GSH-dependent process likely involved with lung injury rather than to changes in 
microvascular permeability or some other process. Changes in cardiac output that may occur in patients could 
be measured and accounted for in the interpretation of 99mTc-HMPAO data. Thus the modeling in these 
preclinical studies is an important step toward that clinical use. 
We developed an approach for studying the pharmacokinetics of a clinical SPECT biomarker, 99mTc-HMPAO, in 
IPL. Experimental and modeling results indicate that tissue GSH is the dominant factor in 99mTc-HMPAO retention 
in lung tissue. This approach allows investigation of questions that cannot readily be addressed in either in vivo 
preclinical or clinical studies. The MATLAB code for the computational model is available for download at the 
model sharing website https://www.physiome.org or upon request to the corresponding author. 
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APPENDIX: DERIVATION OF GOVERNING DIFFERENTIAL EQUATIONS OF 
HMPAO PBPK MODEL 
HMPAO lung uptake is given by the total of oxidized and reduced HMPAO in the pulmonary arteries, pulmonary 
capillary vascular and extravascular regions, and pulmonary veins. A model was developed to determine each of 
these components and hence the resulting lung TAC. 
Single capillary element. 
Each capillary element (Fig. 6) consists of a vascular region and a surrounding extravascular region, with volumes 
𝑉𝑣 and 𝑉𝑒, respectively. The model assumes the following: 
•  The lipophilic oxidized form of HMPAO can diffuse out of the vascular region into the extravascular 
region driven by concentration gradient. 
•  Flow and hence convection are restricted to the vascular region. 
•  Transport within the extravascular region occurs only by diffusion. 
•  Instantaneous radial diffusion of both forms of HMPAO within the vascular and extravascular regions 
(Ref. 3). 
•  Diffusion of both forms in the vascular and extravascular regions in the flow direction (x) is negligible 
compared with axial convective transport (Ref. 3). 
•  The free (i.e., not albumin bound) oxidized form of HMPAO participates in rapidly equilibrating 
interactions with perfusate albumin (BSA) in the vascular region and with other proteins and/or binding 
sites in the extravascular region. 
•  The free oxidized form of HMPAO is converted to the reduced form via a GSH-dependent and a GSH-
independent process. 
•  The GSH-dependent rate of HMPAO reduction in the vascular region is assumed to be zero. 
•  Injected HMPAO is 100% in the oxidized form. 
Under these assumptions and using mass balance and laws of mass action, the temporal and spatial variations in 
the concentrations of the oxidized, 𝑂(𝑡, 𝑥), and reduced, 𝑅(𝑡, 𝑥), forms of HMPAO in the blood and tissue 


























= Ve(𝑘3𝑂eRH + 𝑘2𝑂eGSH) (A5) 
where W = L/µ𝑐 is the average flow velocity within the capillary region and µ𝑐 is the capillary mean transit time 
and x = 0 and x = L are the capillary inlet and outlet, respectively. 𝑂𝑣(𝑥, 𝑡) and 𝑂𝑒(𝑥, 𝑡) are the respective 
vascular and extravascular concentrations of the oxidized form of HMPAO at distance x from the capillary inlet 
and time t. 𝑃v and 𝑃𝐵𝑂𝐵(𝑥, 𝑡) are the respective perfusate %BSA and vascular concentration of the BSA-bound 
form of oxidized HMPAO at x and t. 𝑃e and 𝑃𝑒𝑂𝑒(𝑥, 𝑡) are the respective concentrations of protein and protein-
bound form of oxidized HMPAO within the extravascular region at x and t. GSH and RH are the concentrations of 
glutathione and other reductants, respectively, within the extravascular region. 
Assuming rapidly equilibrating interactions between the oxidized form of HMPAO and albumin (BSA, 𝑃v) in the 
vascular region, we obtain 
𝑘−1𝑂v𝑃v = 𝑘1𝑂v𝑃v (A6) 
If we let Ō𝑣  =  𝑂𝑣 +  𝑂𝑣𝑃𝑣 = total (free + bound) concentration of the oxidized form in 𝑉𝑣, then 








 = equilibrium dissociation constant. 
Similarly, assuming rapidly equilibrating interactions between oxidized HMPAO and proteins (𝑃e) in 𝑉𝑒, the total 
(free + bound) concentration of the oxidized form of HMPAO in 𝑉𝑒 is given by 








 = equilibrium dissociation constant. 
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The boundary (x = 0) and initial (t = 0) conditions are then given by 
?̅?v(𝑥, 0) = ?̅?e(𝑥, 0) = 𝑅e(𝑥, 0) = 0 
?̅?v(0, 𝑡) = 𝐶in(𝑡) and ?̅?e(0, 𝑡) = 𝑅e(0, 𝑡) = 0 
where 𝐶𝑖𝑛(𝑡) is the capillary input function of the injected oxidized form of HMPAO. 
Capillary bed. 
The above PDEs (Eqs. A9–A11) are for a single capillary element. To account for the effect of capillary perfusion 
kinematics on the lung uptake of HMPAO, an organ model was used that accounts for the distribution of 
pulmonary capillary transit times, ℎ𝑐(𝑡), and for the arterial and venous conducting vessels as previously 
described (3, 23). Briefly, the lung is assumed to consist of N parallel, noninteracting capillary elements, each 
with a different transit time 𝑡𝑖, i = 1…N as shown in Fig. A1. Then ℎ𝑐(𝑡) is the result of capillaries with different 
lengths, flows, cross-sectional areas, or any combination of these. However, the per-unit capillary vascular 
volume, exchange surface area, and physical and chemical properties are assumed to be the same for all 
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where Hi is the flow-weighted fraction of capillaries with transit time 𝑡𝑖 and Δt is the transit time increment. All 
capillaries are exposed to the same flow and capillary input function, 𝐶𝑖𝑛(𝑡), under the assumption of random 
coupling conditions between the conducting (i.e., arteries and veins) vessels and exchanging capillaries. For the 
organ model, we assume no dispersion of the injected bolus in the conducting vessels so that the transit time 
distributions of the arteries and the veins are represented by shifted impulse functions (23). 
To determine HMPAO in the capillaries, the governing PDEs above must be solved with the above initial and 
boundary conditions. A direct numerical approach is to first solve the resulting finite difference equations on 
each of the N capillaries, weight the output of each capillary by its corresponding 𝐻𝑖, and sum these weighted 
curves to obtain the concentrations of the oxidized form of HMPAO in the capillary vascular and extravascular 
regions at (x,t). 
Because of the computational complexity of solving the system of PDEs on a distribution of capillaries, we used 
an alternative strategy for obtaining the concentrations at the outlet of the capillaries. The method involves 
solving the governing differential equations for a single capillary with the longest mean transit time and 
subsample from that result as previously described (3, 23) and briefly presented here. Without loss of generality, 
the spatial dimension can be normalized using z = x/L resulting in Ō𝑣(𝑡, 𝑧),  Ō𝑒(𝑡, 𝑧), and 𝑅𝑇(𝑡, 𝑧). Equation 






















with Eqs. A10 and A11 and the initial conditions interpreted accordingly. These PDEs are then solved at each 
Δt and Δz point using finite differences. Because the model produces a continuity wave that travels only in the 
positive z (axial) direction, the time-concentration functions at all z locations along this maximum mean transit 
time capillary can be interpreted as individual outflow concentration curves from capillaries with transit times 
corresponding to the z locations. This can be seen in Fig. A2, where the concentration at the ith node of the 
maximum transit time corresponds with the outflow concentration time curve for a capillary of transit time 𝑡𝑖   =
 𝑖𝛥𝑡 (23). 
Whole organ model. 
HMPAO uptake is given by the total of oxidized and reduced HMPAO in the arteries, capillary vascular and 
extravascular regions, and veins. The lung input function, 𝐶𝑎𝑟𝑡(𝑡), was modeled as a shifted gamma variate 
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} 
Since no dispersion occurs within the conducting arteries, the input to the capillaries, 𝐶𝑖𝑛(𝑡), is a time-shifted 
version of 𝐶𝑎𝑟𝑡(𝑡). The capillary transit time distribution, ℎ𝑐(𝑡), was also represented with a gamma variate 
function with mean transit time (𝜇𝑐) and variance (σ2cσc2) equal to previously measured values reported by 
Ramakrishna et al. (23). Similar to the arteries, transit through the veins is assumed to involve only a time shift 
(equal to the same as the arteries). Therefore output from the lung, 𝐶𝑣𝑒𝑖𝑛(𝑡), is a time-shifted version of the 
capillary outflow curve. Finally, the model lung time-activity curve describing the total amount of 99mTc-HMPAO 
in the lung as a function of time, TAC(t), is the cumulative flow-weighted sum of the lung input concentration 
minus the output concentration at each time, i.e., 





Fig. A1.N parallel pathways corresponding to N capillaries with different mean transit times (𝑡𝑖, where i = 1, 




Fig. A2. Solution of the model partial differential equations for the capillary with the longest transit 
time. 𝐶 𝑖  corresponds to the outflow concentration for each capillary. 𝐻𝑖 is the flow-weighted fraction of 
capillaries with transit time 𝑡𝑖. F, pump flow; z, distance from the capillary inlet; 𝐶𝑖𝑛, capillary input 
function; 𝐶𝑜𝑢𝑡, capillary output function. 
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